<DOC>
	<DOC>NCT00993525</DOC>
	<brief_summary>To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.</brief_summary>
	<brief_title>Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>persistent new vessels,defined as fine retinal vessels with dilated buds or tips covered with hemorrhage or associated with recurrent vitreous hemorrhage or paucity of accompanying fibrous tissue and/or increased in extent compared to previous visit,unresponsive to complete panretinal laser photocoagulation performed at least 4 months prior; logarithm of minimum angle of resolution (logMAR) bestcorrected visual acuity of 0.17 (Snellen equivalent, 20/30) or worse. history of vitrectomy in the study eye; history of thromboembolic event (including myocardial infarction or cerebral vascular accident); major surgery within the prior 6 months or planned within the next 28 days; uncontrolled hypertension; known coagulation abnormalities or current use of anticoagulative medication other than aspirin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>diabetic retinopathy</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>new vessels</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>Persistent retina new vessels</keyword>
</DOC>